Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
Public ClinicalTrials.gov record NCT03116971. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Study With an Open Label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and PK of M3814 in Combination With Etoposide and Cisplatin in Subjects With Treatment-naïve Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
M3814 is an investigational drug under evaluation for treatment of lung cancer. The purpose of the study was to assess the Safety and Efficacy of M3814 in combination with chemotherapy with SCLC ED.
Study identification
- NCT ID
- NCT03116971
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 2 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 24, 2017
- Primary completion
- Feb 28, 2018
- Completion
- Feb 28, 2018
- Last update posted
- Sep 15, 2020
2017 – 2018
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research site | Mesa | Arizona | 85206 | — |
| Research site 1 | Santa Rosa | California | 95403 | — |
| Research site | Santa Rosa | California | 95403 | — |
| Research site | Whittier | California | 90603 | — |
| Research site | Danbury | Connecticut | 06810 | — |
| Research site | Norwalk | Connecticut | 06850 | — |
| Research site | Columbus | Georgia | 31904 | — |
| Research site | Newnan | Georgia | 30265 | — |
| Research site | Topeka | Kansas | 66606 | — |
| Research site | Ashland | Kentucky | 41101 | — |
| Research site | Billings | Montana | 59101 | — |
| Research site | Pinehurst | North Carolina | 28374 | — |
| Research site | Cincinnati | Ohio | 45229 | — |
| Research site | Portland | Oregon | 97213 | — |
| Research site | Philadelphia | Pennsylvania | 19124 | — |
| Research site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03116971, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2020 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03116971 live on ClinicalTrials.gov.